<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>https://www.dottnet.it/articolo/32544092/reumatologia-dall-intelligenza-artificiale-alle-cure-su-misura-le-nuove-frontiere-per-6-milioni-di-italiani</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Reumatologia, dall’intelligenza artificiale alle cure su misura: le nuove frontiere per 6 milioni di italiani</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544092-anteprimearticolidottnet-2026-10-19t092353364.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544095/aifa-nuovi-farmaci-rimborsabili-dal-ssn-voranigo-onivyde-ed-equivalenti</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>AIFA, nuovi farmaci rimborsabili dal SSN: Voranigo, Onivyde ed equivalenti</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544095-3644225.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544096/ibogaina-la-fda-apre-alla-consultazione-sui-trial-precoci-per-dolore-dipendenze-e-ptsd</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Ibogaína, la FDA apre alla consultazione sui trial precoci per dolore, dipendenze e PTSD</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544096-tinydepressedwomanwithanxietysittingonlargepill.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544097/cuore-oltre-520-mila-procedure-mininvasive-in-un-anno-i-dati-diventano-alleati-delle-cure</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Cuore, oltre 520 mila procedure mininvasive in un anno: i dati diventano alleati delle cure</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544097-anteprimearticolidottnet-2026-10-19t103542545.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544093/svapo-tra-gli-adolescenti-l-allarme-dei-pediatri-la-dipendenza-da-nicotina-puo-iniziare-con-consumi-ridotti</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Svapo tra gli adolescenti, l’allarme dei pediatri: la dipendenza da nicotina può iniziare con consumi ridotti</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544093-anteprimearticolidottnet-2026-10-19t094213312.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544094/logopedisti-serve-la-laurea-specialistica-clinica-le-competenze-avanzate-vanno-riconosciute-</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Logopedisti, serve la laurea specialistica clinica: «le competenze avanzate vanno riconosciute»</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544094-anteprimearticolidottnet-2026-10-19t095852074.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544091/tumore-del-pancreas-perche-la-vera-svolta-fa-meno-rumore-dei-miracoli</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Tumore del pancreas, perché la vera svolta fa meno rumore dei miracoli</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544091-anteprimearticolidottnet31.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544099/tumore-del-pancreas-daraxonrasib-verso-l-approvazione-europea-sige-risultati-importanti-ma-attenzione-alle-aspettative-</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Tumore del pancreas, daraxonrasib verso l’approvazione europea. SIGE: «risultati importanti, ma attenzione alle aspettative»</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544099-anteprimearticolidottnet-2026-10-19t111549354.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544081/prac-nove-segnali-di-sicurezza-sotto-la-lente-dell-ema-focus-su-antidiabetici-e-terapie-oncologiche</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>PRAC, nove segnali di sicurezza sotto la lente dell’EMA: focus su antidiabetici e terapie oncologiche</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544081-magnifying-glass-colourful-pills1.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544098/liste-d-attesa-la-corte-dei-conti-265-milioni-non-spesi-in-quattro-anni</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Liste d&#39;attesa, la Corte dei conti: 265 milioni non spesi in quattro anni</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544098-listeattesa2.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544069/salute-femminile-ema-prepara-una-roadmap-per-colmare-i-gap-nello-sviluppo-dei-farmaci</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Salute femminile, EMA prepara una roadmap per colmare i gap nello sviluppo dei farmaci</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544069-31z2vuzgvyide3.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544100/sanita-regionalizzata-anche-i-sindacati-rischiano-di-dividersi</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Sanità regionalizzata, anche i sindacati rischiano di dividersi</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544100-sindacato.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544102/vitiligine-week-dal-23-al-28-novembre-visite-gratuite-in-italia</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Vitiligine Week, dal 23 al 28 novembre visite gratuite in Italia</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544102-anteprimearticolidottnet32.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32543834/i-nifedipina-in-gocce-orali-salativ-20-mg-ml-i-</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>&lt;i&gt;Nifedipina in gocce orali: SALATIV® 20 mg/mL&lt;/i&gt;</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32543834-salativ.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544103/fascicolo-sanitario-57-milioni-di-attivi-ma-quanti-sono-utili-</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Fascicolo sanitario, 57 milioni di attivi. Ma quanti sono utili?</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544103-fse.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544101/tumori-professionali-l-ue-rafforza-i-limiti-sulle-sostanze-nocive</loc>
  <lastmod>2026-10-19T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Tumori professionali, l&#39;Ue rafforza i limiti sulle sostanze nocive</news:title>
   <news:publication_date>2026-10-19</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544101-sostanzecancerogene.jpg</image:loc>
  </image:image>
 </url>
</urlset>